share_log

TD Cowen Maintains Buy on Standard BioTools, Lowers Price Target to $2.75

Benzinga ·  Aug 2 02:27  · Ratings

TD Cowen analyst Daniel Brennan maintains Standard BioTools (NASDAQ:LAB) with a Buy and lowers the price target from $3.5 to $2.75.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment